In a recent review from Biomicrofluidics, the authors unpack the current and future trends in microfluidic technology applications in the fields of antibody discovery and cell line development.

As antibody discovery and cell line development landscapes evolve, researchers are seeking out novel approaches and tools to aid in their research campaigns. These researchers ultimately need to delicately balance speed, precision and throughput when executing these campaigns which, in instances, require screening hundreds of thousands to millions of cells to find that standout clone or antibody sequence.

This review dives into how microfluidic technology can be implemented to achieve the desired speed, precision, and throughput for specific antibody discovery and cell line development workflows. The authors also go one level deeper and breakdown the variety of instruments that are currently on the market and how the specific technology that makes each instrument unique can be applied to fit the needs of any workflow.

✅ Cyto-Mine^® and Cyto-Mine^® Chroma offer the most commercially ready microfluidic device.

✅ Instrument approachability is key.

✅ Robustness vs. Flexibility. Desired applications should align with commercial goals.

✅ Microfluidic chip design is crucial. Sphere Bio offers an off the shelf option that removes the burden of the end user to design chips from scratch.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.